Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma

Zhao, Chenguang; Gao, Shugeng; Xue, Qi; Tan, Fengwei; Gao, Yushun; Mao, Yousheng; Wang, Dali; Zhao, Jun; Yang, Ding; Hong, Qian; Mu, Jianjun

doi:10.21037/jtd-22-393

J Thorac Dis

2022

DOI: 10.21037/jtd-22-393

|View full text |Cite

Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma

Chenguang Zhao¹,

Shugeng Gao²,

Qi Xue³

et al.

Abstract: Background: Pulmonary sarcomatoid carcinoma (PSC) is a kind of rare lung cancer. We aim to analyze the clinical characteristics and prognostic factors of patients with PSC.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, Zhao et al reported the long-term follow-up data of 119 patients with PSC in a single cancer center in China ( 5 ). The authors described the data regarding the main features of patients with PSC and disease prognosis, including median survival and 1-, 3-, and 5-year overall survival based on patient characteristics.…”

mentioning

confidence: 99%

“…However, mixed results exist on the effectiveness of chemotherapy in combination with surgery, and this study did not provide a definite conclusion regarding this point ( 4 , 6 , 8 ). Since a majority of the patients received adjuvant or neoadjuvant chemotherapy in current and previous studies, future studies focusing on the combination of chemotherapy and surgery are warranted ( 5 , 6 ).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Emerging new evidence for the treatment of pulmonary sarcomatoid carcinoma

Akaba¹,

Arimura²,

Tagaya³

2023

J Thorac Dis

View full text Add to dashboard Cite

Lung cancer is a leading cause of cancer-related mortality, accounting for 1.8 million people worldwide in 2020 (1). Pulmonary sarcomatoid carcinoma (PSC) is a rare type of non-small cell lung cancer (NSCLC), characterized by poorly differentiated carcinoma with components of sarcoma or sarcoma-like differentiation. The most recent classification of PSC includes pleomorphic carcinoma, giant cell carcinoma, spindle cell carcinoma, pulmonary blastoma, and carcinosarcoma (2). Owing to the rapid advancement in cancer treatment and elucidation of disease mechanisms, the outcomes of lung cancer have drastically improved over the last decade. However, the prognosis of PSC is still poor compared to other forms of NSCLC (3,4). There is limited data regarding the standard treatment strategy, clinical characteristics, and prognostic factors due to the rarity of the disease. Therefore, this necessitates the accumulation of evidence for PSC.In a recent study, Zhao et al. reported the long-term follow-up data of 119 patients with PSC in a single cancer center in China (5). The authors described the data regarding the main features of patients with PSC and disease prognosis, including median survival and 1-, 3-, and 5-year overall survival based on patient characteristics. In addition, they elucidated that the TNM stage, especially T staging and M staging, was associated with the prognosis of PSC. These data were consistent with previous studies (4,6,7).Interestingly, more than 90% of patients underwent surgery in this study, and this proportion was substantially greater, despite the small number of Stage IV patients. Since surgical resection is the only known curative treatment for PSC, the relatively good overall survival in this study may be partly attributed to a proactive surgical treatment strategy (6). As emphasized by the authors, complete resection of a tumor should be targeted based on the patient's condition. However, mixed results exist on the effectiveness of chemotherapy in combination with surgery, and this study did not provide a definite conclusion regarding this point (4,6,8). Since a majority of the patients received adjuvant or neoadjuvant chemotherapy in current and previous studies, future studies focusing on the combination of chemotherapy and surgery are warranted (5,6).To date, there is no standard treatment regimen for management of advanced-stage PSC. A previous study on a French cohort showed that platinum-based chemotherapy modestly improved the outcomes of patients with PSC (9). However, patients with PSC tend to develop chemotherapy resistance at an early stage, thereby resulting in less efficacy. Therefore, similar to other NSCLCs, other treatment strategies, such as molecular-targeted drugs and immune checkpoint inhibitors, may play an important role in the treatment of advanced-stage PSC. The current study showed that 8/18 (44%) patients with PSC were positive for mutations in genes such as KRAS, EGFR, and ALK. In addition, some PSC patients harbored the MET mutation, and MET and KRAS mutations...

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Emerging new evidence for the treatment of pulmonary sarcomatoid carcinoma

Akaba¹,

Arimura²,

Tagaya³

2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

Pulmonary Carcinosarcoma is a Rare Cancer with a Poor Prognosis – A Retrospective Study

Hakami¹

2023

Clin Cancer Investig J

View full text Add to dashboard Cite

Computed Tomography-Based Radiomics Analysis of Different Machine Learning Approaches for Differentiating Pulmonary Sarcomatoid Carcinoma and Pulmonary Inflammatory Pseudotumor

Zhang,

Fu,

2024

I J Radiol

View full text Add to dashboard Cite

Background: Differentiating between pulmonary sarcomatoid carcinoma (PSC) and pulmonary inflammatory pseudotumor (PIP) is challenging using current conventional diagnostic methods. This lack of distinction significantly impacts subsequent clinical treatment decisions. Objectives: This study was conducted to construct an effective method to distinguish between PSC and PIP based on commonly used computed tomography (CT) images. Patients and Methods: A total of 14 patients with PSC and 76 patients with PIP were retrospectively included in the study for CT imaging. Radiomics features were extracted from non-enhanced CT images, and canonical correlation analysis was performed to reduce redundancy. The final radiomics signature was then identified using the least absolute shrinkage and selection operator (LASSO). Logistic regression (LR), classification and regression trees (CART), support vector machine (SVM), k-nearest neighbors (KNN), and gradient boosting machine (GBM) were used to construct the radiomics models. The performance of these different radiomics models was evaluated using the receiver operating characteristic curve. Results: A total of 1186 radiomics features were extracted from non-enhanced CT images. After dimensionality reduction and selection, 7 valuable features were identified. The performance of 5 machine learning models was evaluated to differentiate between PSC and PIP, and the GBM-based radiomics model demonstrated the best performance. The GBM-based radiomics model achieved an accuracy of 0.922, area under the curve (AUC) of 0.98, F1 score of 0.967, and log loss of 0.161. Compared to conventional clinical-radiological diagnosis, the GBM-based radiomics model showed a significant association (odds ratio [OR] = 8.119; P = 0.006). Conclusion: The implementation of the GBM-based radiomics model has the potential to improve the ability to differentiate between PSC and PIP, thereby influencing the timeliness of subsequent surgical interventions and even the prognosis of patients.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma

Abstract: Background: Pulmonary sarcomatoid carcinoma (PSC) is a kind of rare lung cancer. We aim to analyze the clinical characteristics and prognostic factors of patients with PSC.

Cited by 3 publications

References 30 publications

Emerging new evidence for the treatment of pulmonary sarcomatoid carcinoma

Emerging new evidence for the treatment of pulmonary sarcomatoid carcinoma

Pulmonary Carcinosarcoma is a Rare Cancer with a Poor Prognosis – A Retrospective Study

Computed Tomography-Based Radiomics Analysis of Different Machine Learning Approaches for Differentiating Pulmonary Sarcomatoid Carcinoma and Pulmonary Inflammatory Pseudotumor

Contact Info

Product

Resources

About

Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma

Abstract: Background: Pulmonary sarcomatoid carcinoma (PSC) is a kind of rare lung cancer. We aim to analyze the clinical characteristics and prognostic factors of patients with PSC.

Cited by 3 publications

References 30 publications

Emerging new evidence for the treatment of pulmonary sarcomatoid carcinoma

Emerging new evidence for the treatment of pulmonary sarcomatoid carcinoma

Pulmonary Carcinosarcoma is a Rare Cancer with a Poor Prognosis &ndash; A Retrospective Study

Computed Tomography-Based Radiomics Analysis of Different Machine Learning Approaches for Differentiating Pulmonary Sarcomatoid Carcinoma and Pulmonary Inflammatory Pseudotumor

Contact Info

Product

Resources

About

Pulmonary Carcinosarcoma is a Rare Cancer with a Poor Prognosis – A Retrospective Study